Docoh
Loading...

SYN Synthetic Biologics

APP
Utility
Alkaline Phosphatase Formulations
22 Jul 21
The present invention provides, in part, formulations comprising an alkaline phosphatase (AP)-based agent.
Vincent WACHER, J. Blair WEST, Michael KALEKO, Christian FURLAN FREGUIA
Filed: 29 Mar 21
APP
Utility
Microbiome Protection from Oral Antibiotics
22 Jul 21
This invention provides, in part, various compositions and methods for protecting the gastrointestinal microbiome from antibiotic disruption from orally administered antibiotics.
Michael KALEKO, Sheila CONNELLY
Filed: 28 Jun 17
APP
Utility
Methods of Making Alkaline Phosphatase Agents
24 Jun 21
The present invention relates to, inter alia, compositions and methods, including therapeutic alkaline phosphatases that find use in the treatment of disease, such as microbiome-related diseases.
Maria RODRIGUES, Veronique DE VAUX, Michael KALEKO
Filed: 17 Jun 19
GRANT
Utility
Unknown
15 Jun 21
The invention relates to, in part, improved methods for the production of beta-lactamase using Escherichia coli (E. coli) cells.
Andrew Bristol, Michael Kaleko, Steven Hubert
Filed: 27 Aug 15
GRANT
Utility
Alkaline phosphatase formulations
27 Apr 21
The present invention provides, in part, formulations comprising an alkaline phosphatase (AP)-based agent.
Vincent Wacher, J. Blair West, Michael Kaleko, Christian Furlan Freguia
Filed: 17 Jul 18
APP
Utility
Alkaline Phosphatase Agents for Treatment of Neurodevelopmental Disorders
4 Mar 21
The present invention relates, inter alia, to compositions and methods, including therapeutic alkaline phosphatases that find use in the treatment or prevention of various neurodevelopmental diseases or disorders.
Michael KALEKO, Christian FURLAN FREGUIA, Sheila CONNELLY
Filed: 8 Jan 19
APP
Utility
Intestinal Alkaline Phosphatase Formulations
4 Feb 21
The present invention provides for a formulation comprising an active alkaline phosphatase (AP)-based agent and an enteric agent, wherein the formulation is suitable for releasing a substantial amount of the active AP-based agent in the intestines.
Andrew BRISTOL, Ray STAPLETON, Michael KALEKO, Christian FURLAN FREGUIA, Steven HUBERT, Cristina FREIRE, James GUBBINS
Filed: 20 Mar 19
APP
Utility
Alkaline Phosphatase Agents for Treatment of Radiation Disorders
28 Jan 21
The present invention relates to, inter alia, compositions and methods, including therapeutic alkaline phosphatases that find use in the treatment or prevention of the effects of radiation exposure and/or chemotherapy.
Michael KALEKO, Christian FURLAN FREGUIA, Sheila CONNELLY
Filed: 20 Mar 19
APP
Utility
Anti-methanogenic Lovastatin Analogs or Derivatives and Uses Thereof
21 Jan 21
The present invention relates to, in part, methods for the treatment of methanogen-associated disorders such as, for example, Irritable Bowel Syndrome (IBS) using at least one anti-methanogenic lovastatin analog or derivative.
Mark Pimentel, Vince Wacher
Filed: 29 Jun 20
APP
Utility
Beta-lactamase Formulations and Uses Thereof
14 Jan 21
The present invention provides, in part, formulations comprising a beta-lactamase.
Andrew BRISTOL, Michael KALEKO, Sheila CONNELLY
Filed: 28 Sep 20
APP
Utility
Clinically Efficacious Anti-methanogenic Compositions and Uses
16 Dec 20
The present invention relates to, in part, methods and compositions for the treatment of methanogen-associated disorders such as, for example, Irritable Bowel Syndrome (IBS).
Vincent John Wacher, Mark Pimentel
Filed: 20 Jun 17
APP
Utility
Method and Compositions for Inhibiting or Preventing Adverse Effects of Oral Antibiotics
9 Dec 20
This invention provides, in part, various compositions and methods for protecting the gastrointestinal microbiome from antibiotic disruption.
Michael KALEKO, Sheila CONNELLY, Vincent John WACHER
Filed: 19 Aug 20
GRANT
Utility
Beta-lactamase formulations and uses thereof
9 Nov 20
The present invention provides, in part, formulations comprising a beta-lactamase.
Andrew Bristol, Michael Kaleko, Sheila Connelly
Filed: 23 Aug 18
APP
Utility
Beta-lactamases with Improved Properties for Therapy
4 Nov 20
This invention relates to, in part, compositions of beta-lactamases and methods of using these enzymes in, for example, gastrointestinal tract (GI tract) disorders such as C. difficile infection (CDI).
Michael KALEKO, Sheila CONNELLY
Filed: 23 Jul 20
APP
Utility
Anti-methanogenic Compositions and Uses Thereof
14 Oct 20
The present invention relates to, in part, methods and compositions for the treatment of methanogen-associated disorders such as, for example, Irritable Bowel Syndrome (IBS).
Mark Pimentel, Ruchi Mathur, Steve Kanzer, Vince Wacher
Filed: 26 Apr 20
GRANT
Utility
Method and compositions for inhibiting or preventing adverse effects of oral antibiotics
5 Oct 20
This invention provides, in part, various compositions and methods for protecting the gastrointestinal microbiome from antibiotic disruption.
Michael Kaleko, Sheila Connelly, Vincent John Wacher
Filed: 9 Jul 18
APP
Utility
Safe and Effective Beta-lactamase Dosing for Microbiome Protection
23 Sep 20
The present invention relates to, inter alia, safe and effective doses of a beta-lactamase for, e.g. microbiome protection.
Joseph Sliman
Filed: 3 Jun 20
GRANT
Utility
Beta-lactamases with improved properties for therapy
7 Sep 20
This invention relates to, in part, compositions of beta-lactamases and methods of using these enzymes in, for example, gastrointestinal tract (GI tract) disorders such as C. difficile infection (CDI).
Michael Kaleko, Sheila Connelly
Filed: 23 Jan 20
GRANT
Utility
Anti-methanogenic lovastatin analogs or derivatives and uses thereof
10 Aug 20
The present invention relates to, in part, methods for the treatment of methanogen-associated disorders such as, for example, Irritable Bowel Syndrome (IBS) using at least one anti-methanogenic lovastatin analog or derivative.
Mark Pimentel, Vince Wacher
Filed: 30 Mar 16
APP
Utility
Carbapenemases for Use with Antibiotics for the Protection of the Intestinal Microbiome
15 Jul 20
This invention relates, in part, to various compositions and methods for protecting the gastrointestinal microbiome from antibiotic disruption.
Michael KALEKO, Sheila CONNELLY
Filed: 18 Dec 19
Patents are sorted by USPTO publication date, most recent first